# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2018 Earnings Results

**Report date:** 2019-02-06 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2018

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 3.44%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.84 | N/A | +16.75% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in the company's product pipeline and future growth. They acknowledged challenges but remain focused on innovation.

**Key quotes:**

> Management highlighted strong performance in key product areas.

> They noted ongoing investments in research and development.

> There was an emphasis on maintaining a competitive edge in the market.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron Pharmaceuticals reported a strong earnings per share, beating expectations by a significant margin. However, the stock fell by 3.44% in reaction, likely due to the lack of revenue details and guidance. Investors may be cautious without clear future projections from management.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2018_